Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana R. Halle(Vanderbilt University Medical Center), Veronica Rotemberg(Memorial Sloan Kettering Cancer Center), Florentia Dimitriou(The University of Texas MD Anderson Cancer Center), Ryan J. Sullivan(Dana-Farber Cancer Institute), Anna K. Dewan(Vanderbilt University Medical Center), Nicholas R. Kurtansky(Memorial Sloan Kettering Cancer Center), Alexander M. Menzies(The University of Sydney), Douglas B. Johnson(Vanderbilt University Medical Center), Sunandana Chandra(Northwestern University), T. Otto(Rutgers, The State University of New Jersey), Rebecca Irlmeier(Vanderbilt University Medical Center), Jessica C. Hassel(German Cancer Research Center), Georgina V. Long(The University of Sydney), Allison Betof Warner(Memorial Sloan Kettering Cancer Center), Farzana Y. Zaman(The Alfred Hospital), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Matteo S. Carlino(The University of Sydney), Meghan J. Mooradian(Massachusetts General Hospital), Prachi Bhave(The University of Melbourne), Andrew Haydon(The Alfred Hospital), Fei Ye(University of Miami), Jacob Choi(University of Illinois Chicago), Paras Mehta(Memorial Sloan Kettering Cancer Center), Steven T. Chen(Hess (United States)), Mario E. Lacouture(Garden City Community College)
Cited by 64
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k